Bill Analyses and Ratings

Bill Summary

House Bill 777 comprehensively updates Idaho’s controlled substances schedules by adding newly identified dangerous drugs and removing outdated chemical descriptions. Schedule I gains approximately 15 new substances, including beta-methylacetyl fentanyl, bromazolam, ethylphenidate, ortho-chlorofentanyl, N-desethyl isotonitazene, N-piperidinyl etonitazene, meta-fluorofuranyl fentanyl, para-chlorofentanyl, para-fluoro valeryl fentanyl, ortho-methylcyclopropylfentanyl, and tetrahydrothiofuranyl fentanyl. The bill also moves tapentadol from Schedule II(b) to Schedule II(c), adds thiafentanil and norfentanyl as a fentanyl precursor to Schedule II, adds brexanolone to Schedule IV depressants, and moves serdexmethylphenidate from Schedule IV depressants to Schedule IV stimulants.

Beyond scheduling changes, the bill makes significant administrative and procedural reforms. Registration for manufacturers, distributors, and prescribers changes from annual to biennial. The prescription drug monitoring database section is restructured to expand the definition of ‘delegate’ to include broader health care staff, extend database access to federal prosecutors and investigators, allow notarized or electronically certified patient releases, and consolidate three separate misdemeanor penalty provisions into a single, clearer statute covering misrepresentation, unauthorized disclosure, and credential sharing. The bill also mandates (rather than permits) that controlled substances be sealed upon registration revocation and specifies forfeiture goes to a reverse distributor.

Technical corrections throughout the bill standardize numbering formats (replacing letters with Roman numerals in subsection lists), remove lengthy parenthetical chemical descriptions in favor of common names, add common abbreviations for substances like LSD, MDMA, and marijuana, and delete an obsolete October 2020 implementation date for the prescription drug monitoring program review requirement. The bill takes effect July 1, 2026 under an emergency declaration.

Overall Assessment

This bill’s most significant real-world impact is closing gaps in Idaho’s controlled substances law by adding newly synthesized fentanyl analogs, designer benzodiazepines, and nitazene opioids to Schedule I before they proliferate on the illicit market. Law enforcement gains clearer statutory tools to prosecute trafficking of these substances, and the prescription monitoring database receives strengthened protections against unauthorized access with consolidated, unambiguous criminal penalties. Prescribers and pharmacists benefit from biennial rather than annual registration and a broader, more workable definition of authorized database delegates.